Skip to main content
Midas Edge

IMPACT BIOMEDICAL INC

For the period ended Dec 31, 2023. Filed Feb 20, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 20, 2024

IBO$4.33+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Impact BioMedical, Inc.
February 20, 2024By:/s/ Frank D. Heuszel
Frank D. Heuszel
Chief Executive Officer
(Principal Executive Officer)
February 20, 2024By:/s/ Todd D. Macko
Todd D. Macko
Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

February 20, 2024By:/s/ Frank D. Heuszel
Frank D. Heuszel Chief Executive Officer (Principal Executive Officer)
February 20, 2024By:/s/ Todd D. Macko
Todd D. Macko
Chief Financial Officer (Principal Financial and Accounting Officer)
February 20, 2024By:/s/ Heng Fai Ambrose Chan
Heng Fai Ambrose Chan Chairman of the Board
February 20, 2024By:/s/ Mark Suseck
Mark Suseck Chief Operating Officer
February 20, 2024By:/s/ Dr. Elise Brownell
Dr. Elise Brownell Director
February 20, 2024By:/s/ Melissa Sims
Melissa Sims Director
February 20, 2024By:/s/ Castel Hibbert
Castel Hibbert
Director
February 20, 2024By:/s/ Christian Zimmerman
Christian Zimmerman Director
February 20, 2024By:/s/ David Keene
David Keene
Director
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.